New Delhi, June 16: The Central government has tightened regulations governing the sale of cough syrups across the country by amending the Drugs Rules, 1945, ending a long-standing exemption that allowed their sale in certain small villages without compliance with retail licensing requirements.
The amendment, notified under the Drugs Rules, 1945 (Fifth Amendment), removes the word “syrup” from Schedule K of the rules, a move that will bring the sale and distribution of cough syrups under stricter regulatory oversight.
According to the Ministry of Health and Family Welfare, the change is intended to strengthen public health safeguards, improve monitoring of syrup-based formulations and ensure uniform compliance with existing pharmaceutical regulations across the country.
Schedule K of the Drugs Rules provides exemptions from certain provisions of the Drugs and Cosmetics Act, 1940, and the rules framed under it for specific categories of medicines and circumstances. Until now, one of those exemptions permitted cough syrups to be sold in villages with populations of fewer than 1,000 people without adherence to some retail licensing requirements.
With the latest amendment, that exemption has been withdrawn. As a result, cough syrups can now be sold and dispensed only through duly licensed pharmacies operating in accordance with the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945.
Officials said the decision reflects evolving public health priorities and the need for stronger regulation of medicines that may otherwise be sold without adequate oversight.
The amendment is expected to have particular significance in rural and remote areas where exemptions under Schedule K previously enabled the sale of certain medicines through channels that were not subject to the same regulatory standards as licensed pharmacies.
By requiring sales to take place only through authorized outlets, the government aims to improve accountability in the pharmaceutical supply chain and reduce the risk of misuse, inappropriate dispensing and distribution of medicines outside the regulated framework.
The Health Ministry stated that the revised provisions are intended to promote responsible sale and distribution practices while ensuring that pharmaceutical products are handled in accordance with established safety standards.
Industry stakeholders, including manufacturers, distributors and retailers, have been advised to comply strictly with all licensing and regulatory requirements applicable under the Drugs and Cosmetics Act and related rules.
The move comes amid increasing emphasis on strengthening drug regulation, improving quality assurance and ensuring that medicines are dispensed through authorized channels. Public health experts have long argued that regulated distribution systems help improve patient safety by ensuring proper storage, handling and dispensing of medicines.
The amendment is also expected to increase oversight of cough syrup formulations, some of which contain ingredients that require careful monitoring and appropriate medical supervision.
According to the Ministry, aligning the exemption framework with current public health requirements was a key consideration behind the regulatory change. Officials believe the revised rules will help create greater consistency in medicine sales practices across urban and rural areas.
The notification further reinforces the role of licensed pharmacists and registered pharmacies as critical components of the healthcare delivery system. By limiting sales to authorized establishments, regulators aim to ensure that consumers receive medicines through channels equipped to provide appropriate guidance and maintain regulatory compliance.
The government has also indicated that consumers seeking to purchase such medications will be required to obtain them through licensed pharmacies, with sales subject to applicable regulatory provisions. The ministry noted that adherence to prescribed procedures will support safer use of medicines and strengthen public confidence in the healthcare system.
The amendment marks another step in the government’s broader efforts to improve pharmaceutical governance and enhance patient safety standards. As implementation begins, stakeholders across the healthcare and pharmaceutical sectors are expected to review their operations to ensure compliance with the revised regulatory framework.
Officials maintain that the move will contribute to a more accountable and transparent system for the distribution of cough syrups while supporting public health objectives nationwide.
